Sotuletinib (BLZ945)

規(guī)格	庫(kù)存	目錄價(jià)	會(huì)員專(zhuān)享價(jià)	數(shù)量
5 mg	3-5days	￥600.00	登錄后可見(jiàn)	- +
10 mg	3-5days	￥900.00	登錄后可見(jiàn)	- +
25 mg	3-5days	￥1600.00	登錄后可見(jiàn)	- +

規(guī)格

庫(kù)存

目錄價(jià)

會(huì)員專(zhuān)享價(jià)

數(shù)量

5 mg

3-5days

￥600.00

登錄后可見(jiàn)

- +

10 mg

3-5days

￥900.00

登錄后可見(jiàn)

- +

25 mg

3-5days

￥1600.00

登錄后可見(jiàn)

- +

基本信息

英文名稱(chēng)	Sotuletinib (BLZ945)
中文名稱(chēng)	Sotuletinib (BLZ945)
CAS號(hào)	953769-46-5
分子式	C20H22N4O3S
分子量	398.48
外觀	Off-white to light brown powder
儲(chǔ)存條件	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

產(chǎn)品詳情

Sotuletinib (formerly BLZ945; BLZ-945) is a novel, potent, selective, orally bioactive, and brain-penetrant CSF-1R (colony stimulating factor 1 receptor) inhibitor with potential antitumor activity. It exhibits 1000-fold higher selectivity against its closest receptor tyrosine kinase homologs and inhibits CSF-1R with an IC50 of 1 nM. Glioma-bearing mice demonstrate high in vivo antitumor efficaciousness of BLZ945. Sotuletinib was designated as an orphan drug by the US FDA in August 2022 in order to treat patients suffering from Amyotrophic Lateral Sclerosis (ALS), a progressive neurological disorder that affects nerve cells in the brain and spinal cord and results in loss of motor control.

相關(guān)文獻(xiàn)

抱歉，暫時(shí)沒(méi)有相關(guān)文獻(xiàn)

相關(guān)產(chǎn)品

抱歉，暫時(shí)沒(méi)有相關(guān)產(chǎn)品

瀏覽記錄

CL2550

Sotuletinib (BLZ945)

953769-46-5 98+% 3-5days

￥600.00 5 mg

久久久无码视频,影音先锋女人av噜噜色,久久久久无码国产精品Sm高潮,人人色综合

Sotuletinib (BLZ945)

Sotuletinib (BLZ945)

化學(xué)品安全說(shuō)明書(shū)(MSDS)